Eradication of Prostate Cancer Using F-989

Phase 2

Completed

• Conditions: Prostate Cancer

• Registration Number: NCT01987999
• Lead Sponsor: Optimal Health Research

Brief Summary

The purpose of this study is to confirm the findings of an early study with prostate cancer and to expand our knowledge of treating prostate cancer using F-989.

Detailed Description

Not available

Study Timeline

• Study Start: 2013-02
• Study First Submitted: 2013-11-07
• Study First Submitted QC: 2013-11-13
• Study First Posted: 2013-11-20
• Primary Completion: 2015-12
• Study Completion: 2015-12
• Status Verified: 2019-09
• Last Update Submitted: 2019-09-18
• Last Update Posted: 2019-09-20

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 60

Inclusion Criteria

• Clinical diagnosis of prostate cancer
• Referred to the study by their treating physician

Exclusion Criteria

• Any type of treatment before starting study

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Gleason Score	1 year	A Gleason Score is obtained from the results of a transrectal needle biopsy of the prostate.

Secondary Outcome Measures

Name	Time	Method
Prostate Specific Antigens (PSA)	1 year